To present a case of a patient with severe, refractory non-infectious panuveitis and multiple sclerosis who achieved remission with ofatumumab after failing multiple conventional treatments and experiencing relapses.
Key Findings:
Ofatumumab led to sustained clinical remission and preservation of visual function in the patient, who had a history of retinal vasculitis.
The case supports the role of B cells in the pathogenesis of non-infectious uveitis.
B-cell–targeted therapy may be effective for refractory uveitis, especially in patients with coexisting autoimmune conditions.
Interpretation:
This case underscores the potential of B-cell depletion as a therapeutic strategy in refractory non-infectious uveitis, suggesting a shift in treatment paradigms and the need for further research.
Limitations:
This is a single case report, limiting generalizability.
Long-term outcomes and safety of ofatumumab in this context remain to be established, and there is a lack of long-term follow-up data.
Conclusion:
Ofatumumab may offer a promising treatment option for patients with refractory non-infectious panuveitis, particularly those with concurrent autoimmune disorders.
